Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jun;31(6):915-8.
doi: 10.1007/s10096-011-1404-x. Epub 2011 Sep 16.

Mini review: Hookworm-related cutaneous larva migrans

Affiliations
Review

Mini review: Hookworm-related cutaneous larva migrans

H Feldmeier et al. Eur J Clin Microbiol Infect Dis. 2012 Jun.

Abstract

Hookworm-related cutaneous larva migrans (HrCLM) is a parasitic skin disease caused by the migration of animal hookworm larvae in the epidermis. Since these larvae cannot penetrate the basal membrane of human skin, they remain confined to the epidermis and are unable to develop and complete their lifecycle. By consequence, HrCLM is a self-limiting disease. However, if not treated promptly, the skin pathology may persist for months. HrCLM is endemic in many resource-poor communities in the developing world. In high-income countries, HrCLM occurs sporadically or in the form of small epidemics. Travelers account for the great majority of cases seen by health-care professionals in high-income countries. Transmission occurs when naked skin comes into contact with contaminated soil. Exposure may also occur indoors. Exceptionally, larvae may be transmitted through fomites. The first clinical sign is a small reddish papule. Thereafter, the characteristic serpiginous, slightly elevated, erythematous track becomes visible. Itching becomes more and more intense. Excoriations induced by scratching facilitate bacterial superinfection of the lesion. The diagnosis is essentially clinical. It is supported by a recent travel history and the possibility of exposure. The drug of choice is ivermectin in a single dose (200 μg per kg bodyweight). Repeated treatments with albendazole (400 mg daily) are a good alternative in countries where ivermectin is not available.

PubMed Disclaimer

References

    1. Rev Cubana Med Trop. 1983 Sep-Dec;35(3):303-16 - PubMed
    1. Trop Med Int Health. 1996 Aug;1(4):503-4 - PubMed
    1. South Med J. 1996 Jun;89(6):609-11 - PubMed
    1. Arch Dermatol. 1993 May;129(5):588-91 - PubMed
    1. Clin Exp Dermatol. 2006 Jul;31(4):613-4 - PubMed

LinkOut - more resources